JP2019517813A5 - - Google Patents

Download PDF

Info

Publication number
JP2019517813A5
JP2019517813A5 JP2018566226A JP2018566226A JP2019517813A5 JP 2019517813 A5 JP2019517813 A5 JP 2019517813A5 JP 2018566226 A JP2018566226 A JP 2018566226A JP 2018566226 A JP2018566226 A JP 2018566226A JP 2019517813 A5 JP2019517813 A5 JP 2019517813A5
Authority
JP
Japan
Prior art keywords
antibody
seq
human
chain comprises
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018566226A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019517813A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/037533 external-priority patent/WO2017218691A1/en
Publication of JP2019517813A publication Critical patent/JP2019517813A/ja
Publication of JP2019517813A5 publication Critical patent/JP2019517813A5/ja
Pending legal-status Critical Current

Links

JP2018566226A 2016-06-16 2017-06-14 Ｃｄ８１に対するヒト化及びキメラモノクローナル抗体 Pending JP2019517813A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662351054P 2016-06-16 2016-06-16
US62/351,054 2016-06-16
PCT/US2017/037533 WO2017218691A1 (en) 2016-06-16 2017-06-14 Humanized and chimeric monoclonal antibodies to cd81

Publications (2)

Publication Number Publication Date
JP2019517813A JP2019517813A (ja) 2019-06-27
JP2019517813A5 true JP2019517813A5 (enExample) 2020-07-27

Family

ID=60664252

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018566226A Pending JP2019517813A (ja) 2016-06-16 2017-06-14 Ｃｄ８１に対するヒト化及びキメラモノクローナル抗体

Country Status (9)

Country Link
US (1) US10815306B2 (enExample)
EP (1) EP3471762A4 (enExample)
JP (1) JP2019517813A (enExample)
CN (1) CN109414492A (enExample)
BR (1) BR112018076247A2 (enExample)
CA (1) CA3027942A1 (enExample)
MA (1) MA45404A (enExample)
RU (1) RU2019100102A (enExample)
WO (1) WO2017218691A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4093430A4 (en) 2020-01-21 2024-01-24 Tavotek Biotherapeutics (Hong Kong) Limited AGENTS THAT INTERFERE WITH IL-1 RECEPTOR SIGNALING?
WO2024079192A1 (en) 2022-10-12 2024-04-18 Institut National de la Santé et de la Recherche Médicale Cd81 as a biomarker and biotarget in t-cell malignancies

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
ATE279947T1 (de) 1996-03-18 2004-11-15 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
JP2008520186A (ja) * 2004-10-01 2008-06-19 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ 哺乳類ｅａｇ１イオンチャネルタンパク質に対する新規の抗体
WO2006117782A2 (en) * 2005-05-04 2006-11-09 Quark Pharmaceuticals, Inc. Recombinant antibodies against cd55 and cd59 and uses thereof
PL2161336T5 (pl) * 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
EP1790664A1 (en) * 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
US7858752B2 (en) 2006-12-05 2010-12-28 Abbott Laboratories Recombinant antibodies against hepatitis C virus and methods of obtaining and using same
DK2462161T3 (en) * 2009-08-06 2017-06-06 Immunas Pharma Inc Antibodies specifically binding to A-beta oligomers and their use
US20140030771A1 (en) * 2010-06-09 2014-01-30 Richard C. Yu Compositions and methods for increasing oil production and secretion
AU2011339414A1 (en) * 2010-12-06 2013-07-04 Sumitomo Dainippon Pharma Co., Ltd. Human monoclonal antibody
US8440797B2 (en) * 2010-12-06 2013-05-14 Dainippon Sumitomo Pharma Co., Ltd. Human monoclonal antibody
WO2014063368A1 (zh) * 2012-10-26 2014-05-01 中国医学科学院基础医学研究所 抗人死亡受体5胞外区的人源化单克隆抗体

Similar Documents

Publication Publication Date Title
JP6971153B2 (ja) 多重特異的ｎｋエンゲイジャータンパク質
CN107532188B (zh) Cd20结合分子及其用途
JP2025118630A (ja) 抗ＳＩＲＰ－α抗体及びその使用方法
CN111484555B (zh) 新型双特异性cd3/cd20多肽复合物
CA3175140A1 (en) Novel anti-lilrb4 antibodies and derivative products
EP3409690A1 (en) Humanized anti-cd134 (ox40) antibodies and uses thereof
CN109475603A (zh) 抗pd-l1抗体
IL268593B2 (en) Polypeptides and antibodies having increased cdc and/or agonistic activity and their uses in medicine
EP4214240B1 (en) Anti-ccr8 antibodies
KR20180083944A (ko) 항체 및 이의 사용 방법
JP2018510636A5 (enExample)
JP2014519322A5 (enExample)
JP2015533853A5 (enExample)
EP3965818A1 (en) Materials and methods for modulating t cell mediated immunity
KR20160002864A (ko) 항-cd38 항체 및 감쇠 인터페론 알파-2ｂ와의 융합체
JP2017537082A5 (enExample)
CN113893341B (zh) 抗体
US20200148785A1 (en) Pd-l1 and ta-muc1 antibodies
TW202016142A (zh) 用於治療癌症之組合物及方法
JP2023518189A (ja) デルタ鎖媒介性免疫を調節するための材料及び方法
CA3146977A1 (en) Antibody constructs binding 4-1bb and folate receptor alpha and uses thereof
CN113840839B (zh) 人源化和亲和力成熟的抗ceacam1抗体
KR20230156727A (ko) 항-vsig4 항체 또는 이의 항원 결합 단편 및 용도
KR20240055016A (ko) 면역억제성 b 세포와 연관된 암을 치료하는 방법
RU2019100102A (ru) Гуманизированные и химерные моноклональные антитела против cd81